Bio Protocol to Launch First BioAgent Sale Project Aubrai, with 20% of Total Supply Allocated for Sale
Foresight News reports that the decentralized science (DeSci) platform Bio Protocol will launch its first BioAgent sale project, Aubrai. Aubrai has a total supply of 2 million tokens, of which 20% will be allocated for sale, 6% for the liquidity pool, 15% for the treasury, 20.1% for initial backers, 10% for LEVF, 22% for VitaDAO, and 6.9% for Bio Protocol. The token TGE is scheduled for August 25.
Aubrai is a decentralized scientific agent jointly developed by VitaDAO and BIO, aimed at combating human aging.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A Trader Suffers Over $1.85 Million Loss on ENA Long Position
Bio Protocol Launches Token Launchpad, Allocation Depends on Staked BioXP Shares

Ripple partners with SBI Holdings to promote Ripple USD (RLUSD) in Japan
Trending news
MoreCrypto prices
More








